Janssen Search
Search results
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Dec 04, 2023 United States Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study RARITAN, N.J., Dec. 4, 2023 – Johnson & Johnson announced today that the U.S. Food and Drug ...
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
Jan 18, 2023 The Netherlands Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified LEIDEN, THE NETHERLANDS, (January 18, 2023) – The ...
Gastroenterology – Exploring IBD, Crohn’s and UC
Gastroenterology: Leading the Way to a Cure by Redefining the Treatment Paradigm Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis (UC), is a key area of focus for Janssen. Since introducing the first tumor necrosis ...
Prostate Cancer
Prostate Cancer Janssen has built a legacy of innovation in the treatment of prostate cancer, the second most common cancer in men worldwide. We have developed a novel agent for patients with metastatic castration-resistant prostate cancer (mCRPC) and, ...
Human Microbiome Institute
Human Microbiome Institute Human Microbiome Institute Microbial artwork credit: Mehmet Berkmen, Ph.D. and Maria Peñil Human Microbiome Institute Header Our Vision Article Our Approach Article Our Work Resources Title Join Our Team We are seeking ...
Bert Hartog, Ph.D.
Bert Hartog, Ph.D. SENIOR DIRECTOR, JCI Bert is the Senior Director and Innovation Leader for Janssen Clinical Innovation based in Belgium. As an industry expert in global clinical operations and digital health, he leads transformational innovation ...
Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)
Feb 05, 2024 United States Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for efficacious, safe therapies that offer sustained disease control Nipocalimab is the first ...
TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
Oct 22, 2023 Spain Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, October 22, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Strength in Numbers: How Data Science is Unlocking Innovation, and Transforming the Way We Prevent, Treat and Cure Disease
Strength in Numbers: How Data Science is Unlocking Innovation, and Transforming the Way We Prevent, Treat and Cure Disease When most people hear the term 'data science,' they probably think of people sitting at their laptops feverishly ...
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant P
Mar 01, 2023 United States Niraparib and Abiraterone Acetate Plus Prednisone Has Potential to Address Unmet Need for Patients with BRCA-Positive mCRPC RARITAN, N.J., February 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...